[8-K] Mineralys Therapeutics, Inc. Reports Material Event
Mineralys Therapeutics entered into an underwriting agreement to sell 9,803,921 shares of common stock at a public offering price of $25.50 per share, with the underwriters purchasing the shares from the company at $23.97 per share. The company expects net proceeds of approximately $234.7 million, or about $269.9 million if the underwriters' 30-day option to buy an additional 1,470,588 shares is exercised in full. The offering is expected to close on September 4, 2025, subject to customary closing conditions.
The transaction is being conducted under previously declared Form S-3 registration statements and is accompanied by customary representations, indemnities and closing conditions. The filing includes the underwriting agreement and counsel opinion as exhibits. The company also included a forward-looking statements caution noting that actual results may differ due to market conditions and closing risks.
Mineralys Therapeutics ha sottoscritto un accordo di collocamento per la vendita di 9.803.921 azioni ordinarie a un prezzo di offerta pubblica di $25,50 per azione; gli intermediari acquistano le azioni dalla societ脿 a $23,97 per azione. La societ脿 prevede proventi netti di circa $234,7 milioni, o circa $269,9 milioni se l'opzione di acquisto aggiuntiva di 1.470.588 azioni, esercitabile entro 30 giorni dagli intermediari, venisse interamente esercitata. La chiusura dell'offerta 猫 prevista per il 4 settembre 2025, salvo le consuete condizioni di chiusura.
L'operazione 猫 effettuata in base a precedenti dichiarazioni di registrazione sul modulo S-3 e include le consuete dichiarazioni, indennit脿 e condizioni di chiusura. Il deposito documentale contiene l'accordo di collocamento e il parere legale come allegati. La societ脿 ha inoltre inserito un avviso sui fatti previsionali, precisando che i risultati effettivi potrebbero differire a causa delle condizioni di mercato e dei rischi legati alla chiusura.
Mineralys Therapeutics ha suscrito un acuerdo de colocaci贸n para vender 9.803.921 acciones ordinarias a un precio de oferta p煤blica de $25,50 por acci贸n; los colocadores adquieren las acciones a $23,97 por acci贸n. La compa帽铆a espera ingresos netos de aproximadamente $234,7 millones, o alrededor de $269,9 millones si se ejerce en su totalidad la opci贸n de 30 d铆as de los colocadores para comprar 1.470.588 acciones adicionales. El cierre de la oferta est谩 previsto para el 4 de septiembre de 2025, sujeto a las condiciones habituales de cierre.
La transacci贸n se realiza en virtud de declaraciones de registro Form S-3 previamente presentadas e incluye las representaciones, las indemnizaciones y las condiciones de cierre habituales. La documentaci贸n presentada contiene el acuerdo de colocaci贸n y el dictamen legal como anexos. La compa帽铆a tambi茅n incluy贸 una advertencia sobre declaraciones prospectivas, se帽alando que los resultados reales podr铆an diferir debido a las condiciones del mercado y a riesgos de cierre.
Mineralys Therapeutics電� 瓿惦臧� 欤茧嫻 $25.50搿� 9,803,921欤检潣 氤错喌欤茧ゼ 毵り皝頃橂姅 鞚胳垬瓿勳暯鞚� 觳搓舶頄堨溂氅�, 鞚胳垬鞚�(鞏鸽崝霛检澊韯�)鞚� 須岇偓搿滊秬韯� 欤茧嫻 $23.97鞐� 欤检嫕鞚� 鞚胳垬頃╇媹雼�. 須岇偓電� 靾滌垬鞚奠澊 鞎� $234.7氚彪鞙茧 鞓堨儊霅橂┌, 鞚胳垬鞚胳澊 30鞚� 雮挫棎 於旉皜 1,470,588欤茧ゼ 鞝勲秬 毵れ瀰頃橂姅 鞓奠厴鞚� 頄夓偓頃橂┐ 鞎� $269.9氚彪鞚� 霅� 瓴冹溂搿� 氤搓碃 鞛堨姷雼堧嫟. 瓯半灅 毵堦皭鞚� 韱奠儊鞝侅澑 毵堦皭 臁瓣贝鞚� 鞝勳牅搿� 2025雲� 9鞗� 4鞚�搿� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟.
鞚措矆 瓯半灅電� 鞚措 鞁犼碃霅� Form S-3 霌彪靹滊 頃橃棎靹� 歆勴枆霅橂┌, 韱奠儊鞝侅澑 歆勳垹路氅挫眳臁绊暛路毵堦皭 臁瓣贝鞚� 韽暔霅╇媹雼�. 鞝滌稖 靹滊鞐愲姅 鞚胳垬瓿勳暯瓿� 氩曤 鞚橁铂靹滉皜 觳秬霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 霕愴暅 鞝勲 甏�霠� 歆勳垹鞐� 雽�頃� 欤检潣毳� 旮办灛頃橃棳, 鞁滌灔 靸來櫓瓿� 毵堦皭 毽姢韥 鞚疙暣 鞁れ牅 瓴瓣臣臧� 雼澕歆� 靾� 鞛堨潓鞚� 氇呾嫓頄堨姷雼堧嫟.
Mineralys Therapeutics a conclu un contrat de souscription pour vendre 9 803 921 actions ordinaires 脿 un prix public de 25,50 $ par action ; les souscripteurs ach猫tent les actions 脿 la soci茅t茅 脿 23,97 $ par action. La soci茅t茅 pr茅voit des produits nets d'environ 234,7 M$, ou environ 269,9 M$ si l'option de 30 jours des souscripteurs d'acheter 1 470 588 actions suppl茅mentaires est exerc茅e int茅gralement. La cl么ture de l'offre est pr茅vue le 4 septembre 2025, sous r茅serve des conditions de cl么ture habituelles.
La transaction s'effectue en vertu de d茅clarations d'enregistrement Form S-3 d茅pos茅es ant茅rieurement et s'accompagne des repr茅sentations, indemnit茅s et conditions de cl么ture habituelles. le dossier d茅pos茅 comprend le contrat de souscription et l'avis juridique en tant que pi猫ces jointes. La soci茅t茅 a 茅galement inclus une mise en garde sur les d茅clarations prospectives, pr茅cisant que les r茅sultats r茅els peuvent diff茅rer en raison des conditions de march茅 et des risques li茅s 脿 la cl么ture.
Mineralys Therapeutics hat einen Underwriting-Vertrag zum Verkauf von 9.803.921 Stammaktien zu einem 枚ffentlichen Angebotspreis von $25,50 je Aktie abgeschlossen; die Konsortialf眉hrer erwerben die Aktien von der Gesellschaft zu $23,97 je Aktie. Das Unternehmen erwartet Nettoerl枚se von rund $234,7 Mio. bzw. etwa $269,9 Mio., falls die 30-Tage-Option der Konsortialf眉hrer zum Kauf von zus盲tzlichen 1.470.588 Aktien vollst盲ndig ausge眉bt wird. Der Abschluss des Angebots soll am 4. September 2025 erfolgen, vorbehaltlich der 眉blichen Abschlussbedingungen.
Die Transaktion wird auf Grundlage bereits eingereichter Form S-3-Registrierungsunterlagen durchgef眉hrt und beinhaltet die 眉blichen Zusicherungen, Entsch盲digungen und Abschlussbedingungen. Die Einreichung enth盲lt den Underwriting-Vertrag und ein Rechtsgutachten als Anlagen. Das Unternehmen hat zudem einen Warnhinweis zu zukunftsgerichteten Aussagen aufgenommen, wonach die tats盲chlichen Ergebnisse aufgrund von Marktbedingungen und Abschlussrisiken abweichen k枚nnen.
- Net proceeds of approximately $234.7 million provide meaningful liquidity to fund operations
- Upsize option for 1,470,588 shares allows the company to raise an additional ~$35.2 million if exercised
- Underwritten by prominent banks (BofA, Evercore, Goldman Sachs), indicating institutional distribution support
- Offering conducted under effective Form S-3 registrations, streamlining the process
- Issuance of 9,803,921 new shares will dilute existing shareholders' ownership
- Closing is subject to customary conditions and market risk, so proceeds are not guaranteed
- Forward-looking statements warn actual results may differ due to market conditions and business risks
Insights
TL;DR: Mineralys is raising substantial cash through an at-the-market follow-on offering, improving liquidity while increasing share count.
The deal issues 9.8 million shares at $25.50, producing roughly $234.7 million in net proceeds and up to $269.9 million if the 30-day option is exercised. For a clinical-stage biotech, this level of financing materially bolsters the cash runway and supports ongoing operations or development programs. Pricing and reputable lead managers (BofA, Evercore, Goldman Sachs) suggest demand sufficient to place the offering, though dilution to existing shareholders is an important trade-off. The transaction is conditional on customary closing requirements and subject to market risk.
TL;DR: Transaction follows standard underwriting practices with typical representations and indemnities; governance implications are routine.
The underwriting agreement contains customary representations, warranties, indemnification and termination provisions and is filed as an exhibit. The use of Form S-3 registration statements indicates compliance with SEC registration mechanics. From a governance perspective, the filing documents standard disclosure and does not signal unusual contractual or control provisions. The forward-looking cautionary language adheres to safe-harbor norms.
Mineralys Therapeutics ha sottoscritto un accordo di collocamento per la vendita di 9.803.921 azioni ordinarie a un prezzo di offerta pubblica di $25,50 per azione; gli intermediari acquistano le azioni dalla societ脿 a $23,97 per azione. La societ脿 prevede proventi netti di circa $234,7 milioni, o circa $269,9 milioni se l'opzione di acquisto aggiuntiva di 1.470.588 azioni, esercitabile entro 30 giorni dagli intermediari, venisse interamente esercitata. La chiusura dell'offerta 猫 prevista per il 4 settembre 2025, salvo le consuete condizioni di chiusura.
L'operazione 猫 effettuata in base a precedenti dichiarazioni di registrazione sul modulo S-3 e include le consuete dichiarazioni, indennit脿 e condizioni di chiusura. Il deposito documentale contiene l'accordo di collocamento e il parere legale come allegati. La societ脿 ha inoltre inserito un avviso sui fatti previsionali, precisando che i risultati effettivi potrebbero differire a causa delle condizioni di mercato e dei rischi legati alla chiusura.
Mineralys Therapeutics ha suscrito un acuerdo de colocaci贸n para vender 9.803.921 acciones ordinarias a un precio de oferta p煤blica de $25,50 por acci贸n; los colocadores adquieren las acciones a $23,97 por acci贸n. La compa帽铆a espera ingresos netos de aproximadamente $234,7 millones, o alrededor de $269,9 millones si se ejerce en su totalidad la opci贸n de 30 d铆as de los colocadores para comprar 1.470.588 acciones adicionales. El cierre de la oferta est谩 previsto para el 4 de septiembre de 2025, sujeto a las condiciones habituales de cierre.
La transacci贸n se realiza en virtud de declaraciones de registro Form S-3 previamente presentadas e incluye las representaciones, las indemnizaciones y las condiciones de cierre habituales. La documentaci贸n presentada contiene el acuerdo de colocaci贸n y el dictamen legal como anexos. La compa帽铆a tambi茅n incluy贸 una advertencia sobre declaraciones prospectivas, se帽alando que los resultados reales podr铆an diferir debido a las condiciones del mercado y a riesgos de cierre.
Mineralys Therapeutics電� 瓿惦臧� 欤茧嫻 $25.50搿� 9,803,921欤检潣 氤错喌欤茧ゼ 毵り皝頃橂姅 鞚胳垬瓿勳暯鞚� 觳搓舶頄堨溂氅�, 鞚胳垬鞚�(鞏鸽崝霛检澊韯�)鞚� 須岇偓搿滊秬韯� 欤茧嫻 $23.97鞐� 欤检嫕鞚� 鞚胳垬頃╇媹雼�. 須岇偓電� 靾滌垬鞚奠澊 鞎� $234.7氚彪鞙茧 鞓堨儊霅橂┌, 鞚胳垬鞚胳澊 30鞚� 雮挫棎 於旉皜 1,470,588欤茧ゼ 鞝勲秬 毵れ瀰頃橂姅 鞓奠厴鞚� 頄夓偓頃橂┐ 鞎� $269.9氚彪鞚� 霅� 瓴冹溂搿� 氤搓碃 鞛堨姷雼堧嫟. 瓯半灅 毵堦皭鞚� 韱奠儊鞝侅澑 毵堦皭 臁瓣贝鞚� 鞝勳牅搿� 2025雲� 9鞗� 4鞚�搿� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟.
鞚措矆 瓯半灅電� 鞚措 鞁犼碃霅� Form S-3 霌彪靹滊 頃橃棎靹� 歆勴枆霅橂┌, 韱奠儊鞝侅澑 歆勳垹路氅挫眳臁绊暛路毵堦皭 臁瓣贝鞚� 韽暔霅╇媹雼�. 鞝滌稖 靹滊鞐愲姅 鞚胳垬瓿勳暯瓿� 氩曤 鞚橁铂靹滉皜 觳秬霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 霕愴暅 鞝勲 甏�霠� 歆勳垹鞐� 雽�頃� 欤检潣毳� 旮办灛頃橃棳, 鞁滌灔 靸來櫓瓿� 毵堦皭 毽姢韥 鞚疙暣 鞁れ牅 瓴瓣臣臧� 雼澕歆� 靾� 鞛堨潓鞚� 氇呾嫓頄堨姷雼堧嫟.
Mineralys Therapeutics a conclu un contrat de souscription pour vendre 9 803 921 actions ordinaires 脿 un prix public de 25,50 $ par action ; les souscripteurs ach猫tent les actions 脿 la soci茅t茅 脿 23,97 $ par action. La soci茅t茅 pr茅voit des produits nets d'environ 234,7 M$, ou environ 269,9 M$ si l'option de 30 jours des souscripteurs d'acheter 1 470 588 actions suppl茅mentaires est exerc茅e int茅gralement. La cl么ture de l'offre est pr茅vue le 4 septembre 2025, sous r茅serve des conditions de cl么ture habituelles.
La transaction s'effectue en vertu de d茅clarations d'enregistrement Form S-3 d茅pos茅es ant茅rieurement et s'accompagne des repr茅sentations, indemnit茅s et conditions de cl么ture habituelles. le dossier d茅pos茅 comprend le contrat de souscription et l'avis juridique en tant que pi猫ces jointes. La soci茅t茅 a 茅galement inclus une mise en garde sur les d茅clarations prospectives, pr茅cisant que les r茅sultats r茅els peuvent diff茅rer en raison des conditions de march茅 et des risques li茅s 脿 la cl么ture.
Mineralys Therapeutics hat einen Underwriting-Vertrag zum Verkauf von 9.803.921 Stammaktien zu einem 枚ffentlichen Angebotspreis von $25,50 je Aktie abgeschlossen; die Konsortialf眉hrer erwerben die Aktien von der Gesellschaft zu $23,97 je Aktie. Das Unternehmen erwartet Nettoerl枚se von rund $234,7 Mio. bzw. etwa $269,9 Mio., falls die 30-Tage-Option der Konsortialf眉hrer zum Kauf von zus盲tzlichen 1.470.588 Aktien vollst盲ndig ausge眉bt wird. Der Abschluss des Angebots soll am 4. September 2025 erfolgen, vorbehaltlich der 眉blichen Abschlussbedingungen.
Die Transaktion wird auf Grundlage bereits eingereichter Form S-3-Registrierungsunterlagen durchgef眉hrt und beinhaltet die 眉blichen Zusicherungen, Entsch盲digungen und Abschlussbedingungen. Die Einreichung enth盲lt den Underwriting-Vertrag und ein Rechtsgutachten als Anlagen. Das Unternehmen hat zudem einen Warnhinweis zu zukunftsgerichteten Aussagen aufgenommen, wonach die tats盲chlichen Ergebnisse aufgrund von Marktbedingungen und Abschlussrisiken abweichen k枚nnen.
FAQ
How many shares is Mineralys (MLYS) selling in the offering?
At what price per share was the offering priced?
How much net proceeds will Mineralys receive from the offering?
When is the offering expected to close?
Under what registration statements is the offering being made?
